Advertisement
Research Article

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

  • Daniel B Costa,

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Balázs Halmos,

    Affiliation: University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States of America

    X
  • Amit Kumar,

    Affiliation: Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America

    X
  • Susan T Schumer,

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Mark S Huberman,

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Titus J Boggon,

    Affiliation: Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America

    X
  • Daniel G Tenen,

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Susumu Kobayashi mail

    To whom correspondence should be addressed. E-mail: skobayas@bidmc.harvard.edu

    Affiliation: Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America

    X
  • Published: October 30, 2007
  • DOI: 10.1371/journal.pmed.0040315

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.

Linked Articles

Why Do Cancer Cells Become “Addicted” to Oncogenic Epidermal Growth Factor Receptor?

Ingo Mellinghoff
Perspective | published 30 Oct 2007 | PLOS Medicine
doi:10.1371/journal.pmed.0040321

Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics

Mark S Cragg, Junya Kuroda, Hamsa Puthalakath, David C. S Huang, Andreas Strasser
Research Article | published 30 Oct 2007 | PLOS Medicine
doi:10.1371/journal.pmed.0040316

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

Yixuan Gong, Romel Somwar, Katerina Politi, Marissa Balak, Juliann Chmielecki, Xuejun Jiang, William Pao
Research Article | published 9 Oct 2007 | PLOS Medicine
doi:10.1371/journal.pmed.0040294